We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?
Read MoreHide Full Article
Boston Scientific Corporation (BSX - Free Report) is scheduled to report first-quarter 2019 results on Apr 24, before the opening bell.
In the last reported quarter, the company’s earnings per share beat the Zacks Consensus Estimate by 5.41%. Moreover, it delivered positive earnings surprises in each of the trailing four quarters, the average being 8.85%.
Let’s see, how things are shaping up prior to this announcement.
Key Catalysts
Alike the prior reported quarter, we are upbeat about strong contributions from Boston Scientific’s Cardiovascular business group, which comprises Interventional Cardiology (IC) and Peripheral Interventions (PI). In the last reported quarter, the company generated around 38% of its total revenues from this highest revenue generating segment and registered 8.6% growth on an operational basis.
We are optimistic about the IC business that will help the company maintain impressive global growth, courtesy of an innovative portfolio and robust commercial teams. Complex PCI (percutaneouscoronary intervention) products within IC are growing strongly on the back of successful global expansion efforts. The recent U.S. launch of Eluvia has been a growth driver within this segment. This apart, the company is showing a solid uptick in Ranger DCB and interventional oncology. Meanwhile, the company’s integrations of both VENITI and BTG should ring in the desirable synergies post closure of the acquisitions.
Within IC, the company is demonstrating continued strength in structural heart with WATCHMAN, ACURATE, SENTINEL as well as in both complex PCI (percutaneous coronary intervention) and PCI guidance portfolios. We expect these upsides to contribute to the company’s top line in the upcoming quarterly results.
Boston Scientific Corporation Price and EPS Surprise
More specifically, the company is highly optimistic about a promising start to 2019 within its IC and PI business, banking on its plans to launch a number of products. In this regard, the company received a CE Mark in March and initiated a limited market release of the next-generation WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device in Europe.
This apart, the company expects to see a consistent growth momentum in WATCHMAN this year, riding on the growing adoption by its existing customers and geographic expansions wherein both Japan and China represent a significant opportunity of strength.
The Zacks Consensus Estimate for IC revenues is pegged at $689 million, indicating an increase of 6.8% from the year-ago reported figure.
In recent quarters, the PI business steadily demonstrated a solid uptrend across segments like peripheral arterial disease, venous and interventional oncology. In the last reported quarter, the company commenced the launch of Eluvia in the United States. Per Boston Scientific, Eluvia has a substantial market potential owing to the large addressable patient population, a differentiated, sustained-release technology and the superior clinical outcomes with reduced need for reintervention. We believe, this launch will be accretive to the company’s first-quarter results.
The Zacks Consensus Estimate for first-quarter PI revenues stands at $305 million, suggesting a 5.9% rise from the prior-year reported figure.
Other Factors at Play
Among the other segments, MedSurg is estimated to demonstrate a stable performance led by endoscopy. Urology and Pelvic Health are also projected to surpass the market levels, driven by investment strategies in the key international geographies.
Within endoscopy, the company is expected to display sturdy results, driven by a promising performance within itshemostasis franchise in infection prevention and strong pathology.
Urology and Pelvic Health business should also continue to maintain its growth momentum on the back of a robust global performance.
Boston Scientific’s recent acquisitions added several products (though many are under development) with immense potential to its portfolio. The buyouts of NxThera and nVision in Urology and Pelvic Health, EmCision in Endoscopy and Securus in EP deserve special mention.
The company is gradually fortifying its presence in the emerging markets of Brazil, Russia, India and China (BRIC). In the last reported quarter, business from these markets registered 20% growth, attributable to a commendable progress in China and Latin America.
Boston Scientific is gaining traction in India as well. It is currently targeting about 10 emerging markets to lay emphasis on its growing footprint. The company is also pinning hopes on its core cardiology segment, which is gradually attaining stability with growth in the BRIC nations. This trend is expected to sustain in the to-be-reported quarter as well.
However, the ongoing tensions between the United States and China regarding the imposition of tariffs on imports have raised concerns for major MedTech players as this might affect their top-line numbers in the coming quarters.
Overall, the Zacks Consensus Estimate for total revenues of $2.54 billion implies growth of 6.57% from the prior-year quarter’s reported figure. Also, the consensus estimate for earnings of 36 cents indicates a 9.1% rise from the year-ago quarter's reported figure.
What Our Quantitative Model Predicts
Our proven Zacks model clearly shows that a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has high chances of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Boston Scientific has a Zacks Rank #3, which increases the predictive power of ESP. However, the company has an Earnings ESP of -0.38%, which leaves surprise prediction inconclusive for the stock this reporting cycle.
Stocks Worth a Look
Here are a few medical stocks worth considering from the same space as these comprise the right mix of elements to surpass expectations this time around.
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of +0.26% and a Zacks Rank of 2.
GW Pharmaceuticals plc has an Earnings ESP of +8.33% and is a Zacks #2 Ranked player.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?
Boston Scientific Corporation (BSX - Free Report) is scheduled to report first-quarter 2019 results on Apr 24, before the opening bell.
In the last reported quarter, the company’s earnings per share beat the Zacks Consensus Estimate by 5.41%. Moreover, it delivered positive earnings surprises in each of the trailing four quarters, the average being 8.85%.
Let’s see, how things are shaping up prior to this announcement.
Key Catalysts
Alike the prior reported quarter, we are upbeat about strong contributions from Boston Scientific’s Cardiovascular business group, which comprises Interventional Cardiology (IC) and Peripheral Interventions (PI). In the last reported quarter, the company generated around 38% of its total revenues from this highest revenue generating segment and registered 8.6% growth on an operational basis.
We are optimistic about the IC business that will help the company maintain impressive global growth, courtesy of an innovative portfolio and robust commercial teams. Complex PCI (percutaneouscoronary intervention) products within IC are growing strongly on the back of successful global expansion efforts. The recent U.S. launch of Eluvia has been a growth driver within this segment. This apart, the company is showing a solid uptick in Ranger DCB and interventional oncology. Meanwhile, the company’s integrations of both VENITI and BTG should ring in the desirable synergies post closure of the acquisitions.
Within IC, the company is demonstrating continued strength in structural heart with WATCHMAN, ACURATE, SENTINEL as well as in both complex PCI (percutaneous coronary intervention) and PCI guidance portfolios. We expect these upsides to contribute to the company’s top line in the upcoming quarterly results.
Boston Scientific Corporation Price and EPS Surprise
Boston Scientific Corporation Price and EPS Surprise | Boston Scientific Corporation Quote
More specifically, the company is highly optimistic about a promising start to 2019 within its IC and PI business, banking on its plans to launch a number of products. In this regard, the company received a CE Mark in March and initiated a limited market release of the next-generation WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device in Europe.
This apart, the company expects to see a consistent growth momentum in WATCHMAN this year, riding on the growing adoption by its existing customers and geographic expansions wherein both Japan and China represent a significant opportunity of strength.
The Zacks Consensus Estimate for IC revenues is pegged at $689 million, indicating an increase of 6.8% from the year-ago reported figure.
In recent quarters, the PI business steadily demonstrated a solid uptrend across segments like peripheral arterial disease, venous and interventional oncology. In the last reported quarter, the company commenced the launch of Eluvia in the United States. Per Boston Scientific, Eluvia has a substantial market potential owing to the large addressable patient population, a differentiated, sustained-release technology and the superior clinical outcomes with reduced need for reintervention. We believe, this launch will be accretive to the company’s first-quarter results.
The Zacks Consensus Estimate for first-quarter PI revenues stands at $305 million, suggesting a 5.9% rise from the prior-year reported figure.
Other Factors at Play
Among the other segments, MedSurg is estimated to demonstrate a stable performance led by endoscopy. Urology and Pelvic Health are also projected to surpass the market levels, driven by investment strategies in the key international geographies.
Within endoscopy, the company is expected to display sturdy results, driven by a promising performance within itshemostasis franchise in infection prevention and strong pathology.
Urology and Pelvic Health business should also continue to maintain its growth momentum on the back of a robust global performance.
Boston Scientific’s recent acquisitions added several products (though many are under development) with immense potential to its portfolio. The buyouts of NxThera and nVision in Urology and Pelvic Health, EmCision in Endoscopy and Securus in EP deserve special mention.
The company is gradually fortifying its presence in the emerging markets of Brazil, Russia, India and China (BRIC). In the last reported quarter, business from these markets registered 20% growth, attributable to a commendable progress in China and Latin America.
Boston Scientific is gaining traction in India as well. It is currently targeting about 10 emerging markets to lay emphasis on its growing footprint. The company is also pinning hopes on its core cardiology segment, which is gradually attaining stability with growth in the BRIC nations. This trend is expected to sustain in the to-be-reported quarter as well.
However, the ongoing tensions between the United States and China regarding the imposition of tariffs on imports have raised concerns for major MedTech players as this might affect their top-line numbers in the coming quarters.
Overall, the Zacks Consensus Estimate for total revenues of $2.54 billion implies growth of 6.57% from the prior-year quarter’s reported figure. Also, the consensus estimate for earnings of 36 cents indicates a 9.1% rise from the year-ago quarter's reported figure.
What Our Quantitative Model Predicts
Our proven Zacks model clearly shows that a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has high chances of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Boston Scientific has a Zacks Rank #3, which increases the predictive power of ESP. However, the company has an Earnings ESP of -0.38%, which leaves surprise prediction inconclusive for the stock this reporting cycle.
Stocks Worth a Look
Here are a few medical stocks worth considering from the same space as these comprise the right mix of elements to surpass expectations this time around.
Cerner Corporation has an Earnings ESP of +1.05% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of +0.26% and a Zacks Rank of 2.
GW Pharmaceuticals plc has an Earnings ESP of +8.33% and is a Zacks #2 Ranked player.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>